SCHEMBL5894883

SCHEMBL5894883

CC(C)(C)c1ccc(Oc2cccc(/C=C(\NC(=O)c3ccccc3)C(=O)O)c2)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.67
MAPT P10636 3/20 0.50
FABP1 P07148 1/20 0.48
MEN1 O00255 5/20 0.48
KMT2A Q03164 5/20 0.48
ALDH1A1 P00352 3/20 0.48
MAPK1 P28482 1/20 0.47
HPGD P15428 1/20 0.46
RECQL P46063 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
ATM Q13315 1/20 0.45
EPOR P19235 1/20 0.45
NPC1 O15118 1/20 0.45
POLB P06746 1/20 0.45
CYP2C9 P11712 1/20 0.45
RAB9A P51151 1/20 0.45
PGR P06401 1/20 0.45
ASF1A Q9Y294 1/20 0.44
ADAMTS5 Q9UNA0 1/20 0.44
KCNK9 Q9NPC2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5894898 1.00 LMNA (0.67) LMNAMAPTFABP1MEN1KMT2A
SCHEMBL5894892 1.00 LMNA (0.67) LMNAMAPTFABP1MEN1KMT2A
SCHEMBL5895003 0.91 LMNA (0.76) LMNAMAPTMEN1KMT2AALDH1A1
SCHEMBL5895023 0.91 LMNA (0.76) LMNAMAPTMEN1KMT2AALDH1A1
SCHEMBL5895012 0.91 LMNA (0.76) LMNAMAPTMEN1KMT2AALDH1A1
SCHEMBL5896358 0.89 LMNA (0.70) LMNAMAPTMEN1KMT2AALDH1A1
SCHEMBL5896350 0.89 LMNA (0.70) LMNAMAPTMEN1KMT2AALDH1A1
SCHEMBL5896384 0.89 LMNA (0.70) LMNAMAPTMEN1KMT2AALDH1A1
SCHEMBL5896370 0.89 LMNA (0.70) LMNAMAPTMEN1KMT2AALDH1A1
SCHEMBL5896366 0.89 LMNA (0.70) LMNAMAPTMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7041690-B2 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY, LLC (US) 2006-05-09 US disclosed
US-20060004063-A1 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY, LLC 2006-01-05 US disclosed
EP-1532128-A1 INHIBITORS OF HCV NS5B POLYMERASE Pharmacia & Upjohn Company LLC (US) 2005-05-25 EP disclosed
US-20040142980-A1 Inhibitors of HCV NS5B polymerase PHARMACIA & UPJOHN COMPANY 2004-07-22 US disclosed
WO-2004002977-A1 INHIBITORS OF HCV NS5B POLYMERASE PHARMACIA & UPJOHN COMPANY LLC (US) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142980-A1 Inhibitors of HCV NS5B polymerase POLRMT, POLR1E, CTDSP1 LMNA 4118/4885MAPT 3583/4885FABP1 90/4885
US-20060004063-A1 Inhibitors of HCV NS5B polymerase POLRMT, EIF5B, POLI LMNA 4047/4885MAPT 3589/4885FABP1 180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.